Clinical Trial Update: Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry II [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing BI 1744 CL (5 and 10 mcg) to placebo assessed exercise endurance time in chronic obstructive pulmonary disease; the study is completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• BI 1744 CL

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: COMPLETED | Results posted: 2014-07-08